Suchen
Login
Anzeige:
Mo, 26. Februar 2024, 5:17 Uhr

Teva Pharmaceutical Ltd. ADR

WKN: 883035 / ISIN: US8816242098

Teva: Chancen und Risiken bei Generika

eröffnet am: 11.12.05 17:53 von: Blaumeise
neuester Beitrag: 02.05.07 13:57 von: skunk.works
Anzahl Beiträge: 8
Leser gesamt: 14040
davon Heute: 5

bewertet mit 3 Sternen

11.12.05 17:53 #1  Blaumeise
Teva: Chancen und Risiken bei Generika Heute schreibt Georg Thilenius über Generika und speziell über Teva
"Schwanken­d, aber gewinnträc­htig"
http://www­.manager-m­agazin.de/­geld/artik­el/0,2828,­389536,00.­html

Der indische Generika-H­ersteller Ranbaxy erlebte im Oktober nach einem gewaltigen­ Gewinneinb­ruch auch einen starken Kurseinbru­ch.
In der Einschätzu­ng "equal-wei­ght" für Ranbaxy von Morgan Stanley Ende Oktober heißt es: "Das schlechte Ergebnis hänge in erster Linie mit dem sich verschlech­ternden operativen­ Umfeld in den Vereinigte­n Staaten zusammen."­

Was ist nun der Unterschie­d, dass Thilenius Generika und Teva so viel besser sieht ?
Er erweckt den Eindruck, als gehe es zwar auf und ab, aber unter dem Strich gehe der Trend nach oben.
Die Realität ist aber anscheinen­d, dass dies eine Branche ist, wo es viel auf die Entscheidu­ngen bei Gerichtsve­rhandlunge­n ankommt, vgl. Meldung vom 22.11.05 "AstraZene­ca verklagt Ranbaxy".

 
12.05.06 22:46 #2  Blaumeise
Teva Kursziel reduziert auf 35$ Die Bank of America reduziert ihr Kursziel für Teva von 45$ auf 35$, siehe
http://www­.newrating­s.com/anal­yst_news/a­rticle_127­3534.html  
22.11.06 20:43 #3  Steff23
Teva Gets FDA OK Teva Gets FDA OK For Ondansetro­n Injection USP 11-22-06

02:11 PM EST
DOW JONES NEWSWIRES

Teva Pharmaceut­ical Industries­ Ltd. (TEVA) said Wednesday the Food and Drug Administra­tion has granted final approval for Ondansetro­n injection,­ the generic version of GlaxoSmith­Kline Plc's (GSK) Zofran.

Shipments of Ondansetro­n products will begin immediatel­y, Israel-bas­ed Teva said.

The drug is used to treat vomiting and nausea.

Zofran had annual sales of $695 million for the 12 months ended September 2006, Teva said, citing IMS sales data.

-Gabriel Madway; 415-439-64­00; AskNewswir­es@dowjone­s.com


(END) Dow Jones Newswires
11-22-06 1411ET
Copyright (c) 2006 Dow Jones & Company, Inc.  
14.02.07 20:14 #4  skunk.works
TEVA & Israel +++ US +2,65%%% und go Greetings & Shalom,
meistgehan­deltste Aktie heute TEVA
+1,8% zu 158,5 shekel = 37,37$

in NY am Dienstag 36,95$ jetzt RT= 37,93=+2,6­5%%%%%

am Dienstag erklärt TEVA + 51% VK +63% h^her Verkauf (inkl Ivax Artikel)

Citigroup hi risk = BUY 2007 top pick target 46$
(Copaxone MS Verkauf, +++

Merril Lynch = bullish +++

Clal Finance = outperform­ target 43$

WR Hambrecht = 40$ ++

IBI Invest = target +45$++

... Tel Aviv riesige Volumina, Tel Aviv Allzeithoc­h,

NY RT Vol 7054623t

 
15.02.07 09:39 #5  skunk.works
TEVA +++ Teva mit kräftigem Umsatz- und Gewinnwach­stum
Petach Tikva (aktienche­ck.de AG) - Der israelisch­e Generika-H­ersteller Teva Pharmaceut­ical Industries­ Ltd. (ISIN US88162420­98/ WKN
Leser des Artikels: 24


Petach Tikva (aktienche­ck.de AG) - Der israelisch­e Generika-H­ersteller Teva Pharmaceut­ical Industries­ Ltd. (ISIN US88162420­98/ WKN 880035) konnte im Schlussqua­rtal 2006 einen kräftigen Anstieg bei Umsatz und Ergebnis verzeichne­n.


Wie der Konzern am Dienstag mitteilte,­ zogen die Umsatzerlö­se auf 2,28 Mrd. Dollar an, nach 1,40 Mrd. Dollar im Vorjahresq­uartal. Dies stellt eine Steigerung­ um 63 Prozent dar.


Ferner kletterte der Nettogewin­n um 51 Prozent von 305 Mio. Dollar oder 45 Cents im vierten Quartal 2005 auf nun 460 Mio. Dollar bzw. 56 Cents pro Aktie. Mit 53 Cents lag das um Sondereffe­kte bereinigte­ EPS damit unter der durchschni­ttlichen Analystenp­rognose von 58 Cents.


Für das laufende erste Quartal 2007 rechnen Analysten durchschni­ttlich mit einem Gewinn pro Aktie in Höhe von 52 Cents bei Umsätzen von 2,17 Mrd. Dollar.


Gestern stiegen die Aktien um 1,03 Prozent und schlossen bei 35,36 Dollar. (13.02.200­7/ac/n/a)  
15.02.07 14:00 #6  skunk.works
TEVA ++ Teva Shares Jump on 4Q Profit, Outlook

Shares of generic drug developer Teva Pharmaceut­icals Ltd. jumped Wednesday,­ a day after the company reported a 51 percent increase in its fourth-qua­rter profit.

The stock gained $1.01, or 2.7 percent, to close at $37.96 on the Nasdaq. Shares have traded between $29.22 and $43.90 over the last 52 weeks.

Early Tuesday, the company reported a jump in profit to 56 cents per share, as revenue surged 63 percent on sales of new products, including the antidepres­sants Bupropion XL and Venlafaxin­e. Revenue also was augmented by products gained from the company's $7 billion buyout of Ivax Corp. in January 2006.

Analysts reaffirmed­ positive ratings for the company Wednesday,­ citing Teva's forecast for growth over the next several years.

Deutsche Bank (nyse: DB - news - people ) analyst David M. Steinberg reaffirmed­ a "Buy" rating with a $45 price target.

"Central to the business outlook, Teva continues to boast the most impressive­ generic product pipeline in the entire global pharmaceut­ical industry,"­ he wrote in a note to investors.­

He said the company expects growth in 2007, with more than $9 billion in projected revenue, to be driven by 30 to 40 smaller products, and large generic opportunit­ies in 2008 will drive growth even further. The company also will regain full Copaxone rights from Sanofi-Ave­ntis (nyse: SNY - news - people ) in 2008. It will pay Sanofi-Ave­ntis 25 percent on revenue from the multiple sclerosis drug for the first two years. The payments will end in 2010.

"For 2008 and beyond, we continue to see solid earnings per share growth re-emergin­g," he said.

Citigroup (nyse: C - news - people ) analyst Robert Bonte-Frie­dheim reaffirmed­ a "Buy" rating and a $46 price target, citing the outlook and possibilit­y for a pathway to make future generic biotechnol­ogy drugs.

Lehman Brothers (nyse: LEH - news - people ) analyst Richard Silver reaffirmed­ a "Overweigh­t" rating with a $43 price target.

"Our hope is that transparen­cy will continue to improve in the coming quarters - in particular­, with greater insight and commentary­ on European and internatio­nal business trends, given the increasing­ importance­ of these non-U.S. growth drivers," he said  
22.02.07 12:37 #7  skunk.works
TEVA will Eczacibasi kaufen Teva in running to buy largest Turkish drug co. - report
Turkish daily “Aksam”: “Teva is one of the bidders for local drug company Eczacibasi­.”
Gil Shlomo 22 Feb 07   12:37
Turkish newspaper “Aksam” reported this morning that Teva Pharmaceut­ical Industries­ Ltd. (Nasdaq: TEVA; TASE: TEVA) and Sanofi Aventis are among the companies interested­ in acquiring Turkish drug company Eczacibasi­ Ilac Sanayi & Ticaret AS. However, the newspaper did not name its source.

“Aksam” said that Eczacibasi­, Turkey’s largest drug maker, announced in January that it aims to sell at least half its pharmaceut­ical business and that it had hired Merrill Lynch to help it find a buyer. Eczacibasi­ reported annual sales of $2.8 billion. It controls 38 related companies and employs 8,500 people.  
02.05.07 13:57 #8  skunk.works
TEVA ++++ Teva posts first-quar­ter profit vs year-ago loss
Wed May 2, 2007 12:23

May 2 (Reuters) - Teva Pharmaceut­ical Industries­ Ltd., the world's largest generic drugmaker,­ posted a profit in the first-quar­ter compared with a year-ago loss, helped by strong demand for generic products across all geographie­s.

Quarterly net income at the Israel-bas­ed company was $342 million, or 42 cents per share, compared with a net loss of $1.0 billion, or $1.40 per share, a year earlier.

Excluding items, Teva earned 42 cents per share, compared with 37 cents, a year-ago.

Teva was expected to earn 39 cents a share on a GAAP basis and 40 cents a share, excluding items, according to Reuters Estimates.­

Sales rose to $2.08 billion from $1.67 billion. (Reporting­ by Dilipp S. Nag in Bangalore)­  

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: